Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
NCT01776684 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2013-01-28
Summary
To detect resistance gene from serially collected plasma DNA in non-small cell lung cancer harbouring EGFR activating mutation who are being treated with EGFR TKIs by using castPCR method.
Conditions
- EGFR Mutation Positive Non-small Cell Lung Cancer
Interventions
- DRUG
-
EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
Sponsors & Collaborators
- collaborator INDUSTRY
-
Samsung Medical Center
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2014-05-31
- Completion
- 2015-05-31
Countries
- South Korea
Study Locations
More Related Trials
-
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
NCT02284633 ·Status: UNKNOWN
-
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
NCT01775943 ·Status: UNKNOWN
-
Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study
NCT00717002 ·Status: COMPLETED
-
EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment
NCT02644889 ·Status: UNKNOWN
-
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
NCT04122833 ·Status: UNKNOWN
-
Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA
NCT02629523 ·Status: COMPLETED ·Phase: PHASE2
-
Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
NCT07122882 ·Status: ENROLLING_BY_INVITATION
-
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
NCT03519958 ·Status: WITHDRAWN
-
A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients
NCT06186076 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer
NCT00898924 ·Status: COMPLETED
-
Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations
NCT06062823 ·Status: RECRUITING ·Phase: PHASE2
-
Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer
NCT06595498 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
NGS Genome Analysis in Personalisation of Lung Cancer Treatment
NCT02281214 ·Status: COMPLETED ·Phase: NA
-
Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy
NCT03309462 ·Status: COMPLETED ·Phase: NA
-
Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)
NCT02575560 ·Status: COMPLETED
-
Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR
NCT05767866 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
NCT01106781 ·Status: COMPLETED
-
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
NCT04074993 ·Status: UNKNOWN ·Phase: PHASE2
-
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
NCT02804776 ·Status: COMPLETED ·Phase: PHASE2
-
Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations
NCT05277701 ·Status: UNKNOWN ·Phase: PHASE2
-
EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC
NCT02988141 ·Status: UNKNOWN
-
Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).
NCT03562819 ·Status: COMPLETED
-
Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
NCT05463224 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC
NCT02771314 ·Status: UNKNOWN ·Phase: PHASE2
-
Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients
NCT04708639 ·Status: UNKNOWN